Sign in
WithdrawnNo phase

Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Status
Withdrawn
Started
10 Dec 2025
Ended
14 Jan 2026
Type of study
Observational, 2 groups
Treatments tested
  • Suspected Sepsis Group - Diagnostic Measurements
  • Control Group - Diagnostic Measurements
Record updated
20 February 2026
Why it stopped
Could not get through IRB submission and co-investigators with needed skillsets for study departed organization

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Subjects 18 years old
  • With clinical symptoms suggestive of sepsis Control Group
  • age matched
  • gender matched
  • cardiovascular risk factor matched

Who cannot take part

  • n/a

Where in United States

  • University of Alabama at BirminghamBirmingham, United States

About the trial

What the trial wants to find out

This proposal hypothesizes that mitochondrial bioenergetics in the patient will correspond to mtDNA DAMPs levels and markers of inflammation. We predict these will serve as a prognostic indicator of Sepsis induced cardiac dysfunction (SICD) outcomes. Successful completion of these studies will provide a clearer understanding of the etiology of SICD development and therefore will have a high impact on biomedical research by identifying a new mechanism for understanding sepsis induced organ failure. Importantly, they will also provide a means for more directed and focused therapies, based upon individual bioenergetic/mitochondrial-mediated inflammation profiles. The combined, complementary expertise of the Mentor/co-primary investigators (Drs. Mathru and Ballinger) provide an excellent combination in both basic and translational research. They also have experience conducting studies and publications that will strengthen this research project. Importantly, the methods for characterizing mitochondrial bioenergetics from platelets were developed here at UAB, and methods for quantitative assessment of mtDNA DAMPs have been recently developed.

The 2 groups in the trial

  • suspected sepsis group

    We will perform a prospective observational study of patients admitted to the intensive care units (ICU) with suspected sepsis or septic shock.

    Treatment: Suspected Sepsis Group - Diagnostic Measurements

  • control group

    This group will be compared to suspected sepsis or sepsis shock patients. The control group will be age matched, gender-matched, and cardiovascular risk-factor matched controls.

    Treatment: Control Group - Diagnostic Measurements

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
20 February 2026